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ABSTRACT 
We reported an Idiopathic Thrombocytopenic Purpura (ITP) patient, 66-years-old (woman), with hypokalemia. She received 125 mg three times 
daily of methylprednisolone injection for her ITP. Corticosteroids are the initial treatment of ITP. Her potassium level decrease after she took 
methylprednisolone. Hypokalemia is also a common problem affecting the elderly or geriatric population. Many literatures reported side effects of 
corticosteroid is associated with hypokalemia. Monitoring potassium levels must be check during corticosteroid therapy. In this report, we describe 
the association between corticosteroid with hypokalemia effect. 
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INTRODUCTION 
Idiopathic Thrombocytopenic Purpura (ITP) is an idiopathic 
condition of having thrombocytopenia or a low platelet count. ITP 
is also known as autoimmune thrombocytopenic purpura and 
immune thrombocytopenic purpura because ITP appears to be 
related to antibodies against platelets. ITP is a disease where the 
destruction of peripheral platelet occurs. ITP is divided into acute 
ITP and chronic ITP. The normal range for platelet level in adults 
is between 150,000 and 450,000/mm3. When platelet count 
decreases to below 50,000 mm3, the dangerous bleeding risk 
increase with trauma and the platelet counts below 20,000/mm3 
may increase spontaneous bleeding risk. All therapy for ITP is 
given either orally or intravenously (IV), and the use of 
intramuscular injection should be avoided due to skin bleeding 
risk can occur. One of the medications for ITP is corticosteroids. 
Corticosteroids, typically prednisone, are the primary choice of the 
initial treatment [1]. The treatment can be initiated with the use of 
IV steroids, for instance, with methylprednisolone or prednisone. 
The intravenous steroid with a high dose is commonly indicated in 
a hematologic disorder like ITP [2]. About 70%-80% of patients 
respond to corticosteroids, and about 10%-30% acquire durable 
remission. The other medication is intravenous immunoglobulin 
(IVIg) or IVIg combination with either corticosteroid or platelet 
infusions to increase the platelet count quickly. After the platelet 
count improved, maintenance doses of oral prednisone is 1 to 2 
mg/kg per day, single or divided doses is used. Most ITP cases 
gave a response during the first week of therapy. The oral steroid 
dosage should be gradually reduced after several weeks of use 
therapy [1, 3]. Corticosteroids such as mineralocorticoids and 
glucocorticoids can cause hypokalemia Hereby, we report the ITP 
patient with hypokalemia induced by high dose corticosteroid 
therapy [4, 5].  
CASE REPORT 
A Woman, 66 y old. She admitted to the hospital with diagnosed ITP 
(Idiopathic Thrombocytopenic Purpura). Her symptom is purpura. 
She also has hypertension. For the first day, when she admitted to 
the hospital, her laboratory test showed an abnormal result. The 
result for thrombocyte was 5 x 103/ul (normal value 150-400 x 
103/uL) and potassium 3.1 mEq/l (normal value range 3.5-5.1 
mEq/l). She took methylprednisolone injection 125 mg three times 
daily, eltrombopag olamine 25 mg tablet two tablets once daily, 
amlodipine 10 mg tablet once daily, potassium supplement 600 mg 
tablet once daily, pantoprazole injection 40 mg twice daily, 
carbazochrome injection 10 mg three times daily. The next day, 
methylprednisolone dosage decrease to 125 mg twice daily, and day 
3 to 125 mg once daily. On day 4, methylprednisolone dosage form 
was changed from injection to oral. After 8 care days at the hospital, 
she felt malaise or fatigue. And then, she has diagnosed 
hypokalemia, with potassium level was 2.3 mEq/l. She took 
potassium intravenous for potassium correction. Three days after 
correction, her potassium level to be normal (table 1). 
  
Table 1: Result of thrombocyte and potassium concentration level after methylprednisolone administration 
Labs test Normal value Unit Day (d) 
1 2 3 4 6 7 8 9 10 11 
Thrombocyte 150-400 103/ul 5 18 65 68 91 148 64 12  82 
Potassium 3.5-5.1 mEq/l 3.1      2.3 2.9 3.1 3.9 
 
In this case, the Naranjo adverse drug reaction probability scale was 
applied to quantify the degree of association between 
methylprednisolone and hypokalemia and it was found to be score 8 
(probable). Hypokalemia may be caused by methylprednisolone 
therapy. 
DISCUSSION 
Glucocorticoids are the most potent and effective anti-inflammatory 
agents for chronic and acute diseases in clinical practice [2, 6]. 
Methylprednisolone (MP) is an intermediate-acting corticosteroid, 
with a half-life of 12-36 h, potent anti-inflammatory therapy. 
Methylprednisolone has potency 1.25 times compared to 
prednisolone. One of the adverse drug reactions after high dose 
glucocorticoid administration is hypokalemia [2]. Electrolyte 
disturbances such as hypokalemia are frequent in patients treated 
with prednisolone and methylprednisolone [4, 6, 7]. Some reports 
said hypokalemia and muscle weakness occurred after the use of 
methylprednisolone agents [8-11]. 
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Hypokalemia is a condition of serum potassium level of less than 
3.5 mEq/l. The normal range of serum potassium level is 3.5 to 5 
mEq/l. The severity, levels, and symptoms of hypokalemia can be 
seen in the table below [4]. Electrolyte imbalance, such as 
hypokalemia, usually occurs in the elderly. The prevalence of 
hypokalemia case inpatient elderly (above 65 y old) was found 
3.24%. The incidence of hypokalemia increases according to age 
increase, the number of comorbidities, or use of other agents that 
may cause to increased risk of hypokalemia, especially in the 
elderly [5, 12]. 
 
Table 2: Severity, levels, and symptoms of hypokalemia [4] 
Severity Level (mEq/l) Symptoms 
Mild 3.0-3.5  asymptomatic 
Moderate 2.5-3.0 Cramping, malaise, myalgia, weakness 
Severe <2.5 Tachyarrhythmias, bradyarrhythmias, paralysis 
 
Mechanism of glucocorticoids induce hypokalemia by transcellular 
potassium shifts such as increased Na+/K—ATPase pool in 
skeletal muscle and may be mediated by insulin or amylin. Other 
mechanisms of medications cause hypokalemia, including 
increased renal sodium loss or fluid retention, and/or stool loss [4, 
5, 13-15]. 
A patient with polymyositis was treated with 0.5 g/day 
methylprednisolone for a 3-day course, and the patient has 
hypokalemia. After steroid use discontinued, potassium level 
increases [16]. In a study in juvenile rheumatoid arthritis, the side 
effect of methylprednisolone was hypokalemia and hyponatremia 
[2]. Another report said hypokalemia and myopathy event occurred 
after corticosteroid therapy with high dose [13]. Mild and moderate 
hypokalemia (18.18%) has reported in patients who for three days, 
received 1 gram of intravenous methylprednisolone [17].  
A 25-year-old Japanese man with hyperthyroid–related hypokalemia 
worsened by steroid therapy. The patient has ventricular fibrillation 
and paralysis worsened after receiving methylprednisolone infusion 
[18]. Drugs that can induce hypokalemic periodic paralysis (hpoPP) 
include beta mimetics, insulin, corticosteroids, and diuretics [19]. A 
patient experienced thyrotoxic periodic paralysis (TPP) after 
received dexamethasone therapy. TPP can be diagnoses in a patient 
with hypokalemia symptoms and thyrotoxicosis. Some cases 
reported prednisolone and methylprednisolone can induce the TPP 
event. An unusual presentation of TPP due to a high dose of 
glucocorticoids [14, 15, 20, 21]. 
Corticosteroid, especially for steroid pulse therapy, can induce 
cardiac arrhythmias, such as tachyarrhythmias and 
bradyarrhythmias [2, 22]. From the basic electrophysiologic 
viewpoint, corticosteroids affect cardiac calcium channels and also 
potassium channels [22]. A case of hypokalemia occurred after 
starting injection methylprednisolone in the rheumatoid patient 
and resolved after its withdrawal [7]. For mild-to-moderate 
hypokalemia case could be treated with oral potassium 
supplements, and if a patient cannot take oral supplements or with 
severe hypokalemia case require intravenous (IV) potassium as 
replacement therapy [4]. 
CONCLUSION 
Methylprednisolone injection can induce hypokalemia. Serum 
potassium level must be checked before high dose steroid treatment 
and monitoring therapy is also needed. The clinical pharmacists or 
physicians, as early as possible, must identify potential adverse drug 




First author (Sherly Tandi Arrang) conducted the search, collected 
the reference articles, and wrote the manuscript; the second author 
(Fonny Cokro) reviewed the manuscript. 
CONFLICTS OF INTERESTS 
The authors declare no conflicts of interest 
REFERENCES 
1. Kayal L, Jayachandran, Singh K. Idiopathic thrombocytopenic 
purpura. Contemp Clin Dent 2014;5:410–4. 
2. Sinha A, Bagga A. Pulse steroid therapy. Indian J Pediatr 
2008;75:1057-66. 
3. Nomura S. Advances in diagnosis and treatments for immune 
thrombocytopenia. Clin Med Insight: Blood Disorders 
2016;9:15-22. 
4. Veltri KT, Mason C. Medication-induced hypokalemia. 
Pharmacovigilance Forum 2015;40:185-90.  
5. Weiss BD. Medication-induced hypokalemia: a common 
problem. Elder Care; 2015. 
6. Perez HET. Glucose disturbances in non-diabetic patients 
receiving acute treatment with methylprednisolone pulses. Rev 
Assoc Med Bras 2012;58:125-8. 
7. Roshni PR, Sai Keerthana PC, Khrishna PR. Steroid-induced 
hypokalemia-a case report. Int J Pharm Sci Rev Res 
2017;42:42-3. 
8. Buyukcam F, Calik M, Erkuran MK, Akay H. Case report, 
hypokalemia, and muscle paralysis after low dose 
methylprednisolone. Am J Emerg Med 2011;29:573. 
9. Bonnette B, Chauffert B, Martin F. Side-effects of high-dose 
intravenous (pulse) methylprednisolone therapy cured by 
potassium infusion. Br J Rheumatol 1998;37:109. 
10. Soriano PK, Bhattarai M, Vogler CN, Hudali TH. A case of 
trigger-point injection-induced hypokalemic paralysis. Am J 
Case Rep 2017;18:454-7.  
11. Knox Macaulay HHM, Rehman JU, Zadjali SA, Fawaz NA, Al 
Kindi S. Idiopathic thrombocytopenic purpura and 
hypokalaemic dRTA with compensated haemolysis and striking 
acanthocytosis in a band 3 (SLC4A1/AE1) A858D homozygote. 
Ann Hematol 2013;92:53-4. 
12. Bardak S. Community-acquired hypokalemia in elderly 
patients: related factors and clinical outcomes. Int Urol Nephrol 
2017;49:483-9. 
13. Tsai WS, Wu CP, Hsu YS. Life-threatening hypokalemia in an 
asthmatic patient treated with high-dose hydrocortisone. Am J 
Med Sci 2004;327:152-5. 
14. Wongraoprasert S, Buranasupkajorn P, Sridama V, Snabboon T. 
Thyrotoxic periodic paralysis induced by pulse 
methylprednisolone. Int Med 2007;46:1431-3. 
15. Arzel Hezode M. Glucocorticoids may trigger attacks in several 
types of periodic paralysis. Neuromuscular Disorders 
2009;9:217-9. 
16. Wu C. Hypokalemic myopathy in primary aldosteronism: a case 
report. Exp Ther Med 2016;12:4064-6. 
17. Tamez Perez HE, Cisneros Perez V, Cedillo Rodriguez JA, Diaz 
De Leon-Gonzalez E, Torres Valenzuela M, Tamez Pena AL, et 
al. Prevalence of hypokalemia in patients with 
methylprednisolone pulse therapy. Rev Invest Clin 
2009;61:194-7. 
18. Miyashita. Case report: ventricular fibrillation due to severe by 
steroid treatment in a patient with thyrotoxic periodic 
paralysis. Int Med 2006;45:11-3.  
19. Erturk O, Ozlu C. Hypokalemic periodic paralysis that 
presented with hemiparesis after dexamethasone injection. 
Turk J Neurol 2006;22:141-2. 
Arrang et al. 
Int J Pharm Pharm Sci, Vol 12, Issue 7, 83-85 
85 
20. Lee EJ, Kim TK, Kwon MJ, Lee SH, Park JH. Thyrotoxic periodic 
paralysis induced by dexamethasone. Endocrinol Metab 
2012;27:299-302. 
21. Tigas S, Papachilleos P, Ligkros N, Andrikoula M, Tsatsoulis A. 
Hypokalemic paralysis following administration of intravenous 
methylprednisolone in a patient with graves thyrotoxicosis and 
ophthalmopathy. Hormones 2011;10:313-6.  
22. Sakamoto N. Three cases of corticosteroid therapy triggering 
ventricular fibrillation in J-wave syndromes. Heart Vessels 
2014;29:867–72.
 
